Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantWomenWomen's HealthCombined Modality TherapyAntineoplastic AgentsCisplatinTreatment OutcomeCyclophosphamideDoxorubicinNeoadjuvant TherapyDisease-Free SurvivalSurvival AnalysisPrognosisEtoposideBreast NeoplasmsNeoplasm StagingSurvival RateDrug Administration ScheduleLung NeoplasmsMethotrexateFollow-Up StudiesCarboplatinPaclitaxelNeoplasm Recurrence, LocalVinblastineInduction ChemotherapyPregnant WomenTaxoidsBattered WomenTime FactorsNeoplasmsIfosfamideDrug Resistance, NeoplasmOvarian NeoplasmsBleomycinDeoxycytidineAntimetabolites, AntineoplasticOrganoplatinum CompoundsPregnancyAnthracyclinesAge FactorsAntineoplastic Agents, AlkylatingCohort StudiesRisk FactorsChemotherapy, Cancer, Regional PerfusionCytarabineSalvage TherapyNeoplasm MetastasisCarcinoma, Non-Small-Cell LungWomen's Health ServicesAdenocarcinomaVomitingRadiotherapy, AdjuvantWomen's RightsNauseaPostmenopauseTesticular NeoplasmsNeutropeniaLymphoma, Non-HodgkinTransplantation, AutologousColorectal NeoplasmsAntineoplastic Agents, PhytogenicHodgkin DiseaseRadiotherapyClinical Trials as TopicQuestionnairesSex FactorsKaplan-Meier EstimateRecurrenceAntibiotics, AntineoplasticPremenopauseDacarbazineWomen, WorkingTumor Markers, BiologicalNeoplasms, Germ Cell and EmbryonalCarmustineRandomized Controlled Trials as TopicProspective StudiesGranulocyte Colony-Stimulating FactorMenopauseUnited StatesBrain NeoplasmsLomustineBone NeoplasmsProportional Hazards ModelsDose-Response Relationship, DrugCamptothecinPlatinum CompoundsLymphatic MetastasisAntiemeticsCross-Sectional StudiesIncidenceInfusions, Intra-ArterialPeritoneal NeoplasmsMelphalanOsteosarcomaQuality of LifeDrug TherapyLiver Neoplasms